|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramnath N, Dilling TJ, Harris LJ, Kim AW,
Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg
DA: Treatment of stage III non-small cell lung cancer: Diagnosis
and management of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest.
143:(Suppl. 5). eS314–S340. 2013. View Article : Google Scholar
|
|
4
|
Cao Q, Mao ZD, Shi YJ, Chen Y, Sun Y,
Zhang Q, Song L and Peng LP: MicroRNA-7 inhibits cell
proliferation, migration and invasion in human non-small cell lung
cancer cells by targeting FAK through ERK/MAPK signaling pathway.
Oncotarget. 7:77468–77481. 2016.PubMed/NCBI
|
|
5
|
Xu W, Yang G, Xu Y, Zhang Q, Fu Q, Yu J,
Yu M, Zhao W, Yang Z, Hu F, et al: The possibility of traditional
Chinese Medicine as maintenance therapy for advanced nonsmall cell
lung cancer. Evid Based Complement Alternat Med. 2014:2789172014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H, et al: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5:(Suppl 4).
S389–S396. 2013.PubMed/NCBI
|
|
7
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L, Kunkler I, et al: EUROCARE-4 Working
Group: Recent cancer survival in Europe: A 2000–02 period analysis
of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Highlights in NSCLC from the 2014 American
Society of Clinical Oncology annual meeting. Clin Adv Hematol
Oncol. 12:(Suppl 18). S7–S16. 2014.
|
|
9
|
Mountain CF: Revisions in the
International System for Staging Lung Cancer. Chest. 111:1710–1717.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosell R, Bivona TG and Karachaliou N:
Genetics and biomarkers in personalisation of lung cancer
treatment. Lancet. 382:720–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang L, Liu X, Chen Z, Jin Y, Heidbreder
CE, Kolokythas A, Wang A, Dai Y and Zhou X: MicroRNA-7 targets
IGF1R (insulin-like growth factor 1 receptor) in tongue squamous
cell carcinoma cells. Biochem J. 432:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiong Y, Zhang L, Holloway AK, Wu X, Su L
and Kebebew E: MiR-886-3p regulates cell proliferation and
migration, and is dysregulated in familial non-medullary thyroid
cancer. PLoS One. 6:e247172011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Broderick JA and Zamore PD: MicroRNA
therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li C, Dong J, Han Z and Zhang K:
MicroRNA-219-5p represses the proliferation, migration, and
invasion of gastric cancer cells by targeting the
LRH-1/Wnt/b-catenin signaling pathway. Oncol Res. 25:617–627. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu SG, Huang YJ, Bao B, Wu LM, Dong J, Liu
XH, Li ZH, Wang XY, Wang L, Chen BJ, et al: miR-508-5p acts as an
anti-oncogene by targeting MESDC1 in hepatocellular carcinoma.
Neoplasma. 64:40–47. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li JZ, Li J, Wang HQ, Li X, Wen B and Wang
YJ: MiR-141-3p promotes prostate cancer cell proliferation through
inhibiting kruppel-like factor-9 expression. Biochem Biophys Res
Commun. 482:1381–1386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu D, Niu X, Pan H, Zhou Y, Zhang Z, Qu P
and Zhou J: Tumor-suppressing effects of microRNA-429 in human
renal cell carcinoma via the downregulation of Sp1. Oncol Lett.
12:2906–2911. 2016.PubMed/NCBI
|
|
22
|
Ma J, Yu J, Liu J, Yang X, Lou M, Liu J,
Feng F, Ji P and Wang L: MicroRNA-302a targets GAB2 to suppress
cell proliferation, migration and invasion of glioma. Oncol Rep.
37:1159–1167. 2017.PubMed/NCBI
|
|
23
|
Ma W, Ma CN, Zhou NN, Li XD and Zhang YJ:
Up-regulation of miR-328-3p sensitizes non-small cell lung cancer
to radiotherapy. Sci Rep. 6:316512016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maugeri-Saccà M, Coppola V, Bonci D and De
Maria R: MicroRNAs and prostate cancer: From preclinical research
to translational oncology. Cancer J. 18:253–261. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khan S, Brougham CL, Ryan J, Sahrudin A,
O'Neill G, Wall D, Curran C, Newell J, Kerin MJ and Dwyer RM:
miR-379 regulates cyclin B1 expression and is decreased in breast
cancer. PLoS One. 8:e687532013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gururajan M, Josson S, Chu GC, Lu CL, Lu
YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, et al: miR-154*
and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate
epithelial to mesenchymal transition and bone metastasis of
prostate cancer. Clin Cancer Res. 20:6559–6569. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen JS, Li HS, Huang JQ, Dong SH, Huang
ZJ, Yi W, Zhan GF, Feng JT, Sun JC and Huang XH: MicroRNA-379-5p
inhibits tumor invasion and metastasis by targeting FAK/AKT
signaling in hepatocellular carcinoma. Cancer Lett. 375:73–83.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Z, Shen J, Chan MT and Wu WK:
MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1.
J Cell Mol Med. 21:315–323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hao GJ, Hao HJ, Ding YH, Wen H, Li XF,
Wang QR and Zhang BB: Suppression of EIF4G2 by miR-379 potentiates
the cisplatin chemosensitivity in nonsmall cell lung cancer cells.
FEBS Lett. 591:636–645. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin M, Guan X, Liao Z and Wei Q:
Insulin-like growth factor-1 receptor-targeted therapy for
non-small cell lung cancer: A mini review. Am J Transl Res.
1:101–114. 2009.PubMed/NCBI
|
|
32
|
Qian J, Dong A, Kong M, Ma Z, Fan J and
Jiang G: Suppression of type 1 insulin-like growth factor receptor
expression by small interfering RNA inhibits A549 human lung cancer
cell invasion in vitro and metastasis in xenograft nude mice. Acta
Biochim Biophys Sin (Shanghai). 39:137–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim YH, Sumiyoshi S, Hashimoto S, Masago
K, Togashi Y, Sakamori Y, Okuda C, Mio T and Mishima M: Expressions
of insulin-like growth factor receptor-1 and insulin-like growth
factor binding protein 3 in advanced non-small-cell lung cancer.
Clin Lung Cancer. 13:385–390. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cao H, Dong W, Shen H, Xu J, Zhu L, Liu Q
and Du J: Combinational therapy enhances the effects of anti-IGF-1R
mAb Figitumumab to target small cell lung cancer. PLoS One.
10:e01358442015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang W, Liu K, Liu S, Ji B, Wang Y and
Liu Y: MicroRNA-133a functions as a tumor suppressor by targeting
IGF-1R in hepatocellular carcinoma. Tumour Biol. 36:9779–9788.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Osaki LH and Gama P: MAPKs and signal
transduction in the control of gastrointestinal epithelial cell
proliferation and differentiation. Int J Mol Sci. 14:10143–10161.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cao Z, Liu LZ, Dixon DA, Zheng JZ,
Chandran B and Jiang BH: Insulin-like growth factor-I induces
cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling
pathways in human ovarian cancer cells. Cell Signal. 19:1542–1553.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Z, Li B, Niu L and Ge L: miR-592
functions as a tumor suppressor in human non-small cell lung cancer
by targeting SOX9. Oncol Rep. 37:297–304. 2017.PubMed/NCBI
|
|
39
|
Li H, Ouyang R, Wang Z, Zhou W, Chen H,
Jiang Y, Zhang Y, Li H, Liao M, Wang W, et al: MiR-150 promotes
cellular metastasis in non-small cell lung cancer by targeting
FOXO4. Sci Rep. 6:390012016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pei K, Zhu JJ, Wang CE, Xie QL and Guo JY:
MicroRNA-185-5p modulates chemosensitivity of human non-small cell
lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol
Sci. 20:4697–4704. 2016.PubMed/NCBI
|
|
41
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yamamoto K, Seike M, Takeuchi S, Soeno C,
Miyanaga A, Noro R, Minegishi Y, Kubota K and Gemma A: MiR-379/411
cluster regulates IL-18 and contributes to drug resistance in
malignant pleural mesothelioma. Oncol Rep. 32:2365–2372.
2014.PubMed/NCBI
|
|
43
|
Hu Q, Gong JP, Li J, Zhong SL, Chen WX,
Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH, et al: Down-regulation of
miRNA-452 is associated with adriamycin-resistance in breast cancer
cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li ECJ, Shao D, Zhang D, Pan Y, Chen L and
Zhang X: The insulin-like growth factor-I receptor inhibitor
picropodophyllin-induced selective apoptosis of hepatocellular
carcinoma cell through a caspase-dependent mitochondrial pathway.
Oncol Res. 21:103–110. 2013.PubMed/NCBI
|
|
45
|
Wang YH, Han XD, Qiu Y, Xiong J, Yu Y,
Wang B, Zhu ZZ, Qian BP, Chen YX, Wang SF, et al: Increased
expression of insulin-like growth factor-1 receptor is correlated
with tumor metastasis and prognosis in patients with osteosarcoma.
J Surg Oncol. 105:235–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ma Y, Cheng Q, Ren Z, Xu L, Zhao Y, Sun J,
Hu S and Xiao W: Induction of IGF-1R expression by EGR-1
facilitates the growth of prostate cancer cells. Cancer Lett.
317:150–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sichani MM, Yazdi FS, Moghaddam NA,
Chehrei A, Kabiri M, Naeimi A and Taheri D: Prognostic value of
insulin- like growth factor-I receptor expression in renal cell
carcinoma. Saudi J Kidney Dis Transpl. 21:69–74. 2010.PubMed/NCBI
|
|
48
|
Gryko M, Kiśluk J, Cepowicz D, Zińczuk J,
Kamocki Z, Guzińska-Ustymowicz K, Pryczynicz A, Czyżewska J, Kemona
A and Kędra B: Expression of insulin-like growth factor receptor
type 1 correlate with lymphatic metastases in human gastric cancer.
Pol J Pathol. 65:135–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xie QX, Lin XC, Zhang MF, Han CX and Guo
YH: Expression of IGF-I and IGF-IR in bladder cancer. Chin J
Cancer. 23:707–709. 2004.(In Chinese).
|
|
50
|
Pollak MN: Insulin-like growth factors and
neoplasia. Novartis Found Symp. 262:84–98; discussion 98–107,
265–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Werner H and LeRoith D: The role of the
insulin-like growth factor system in human cancer. Adv Cancer Res.
68:183–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
|
53
|
King H, Aleksic T, Haluska P and Macaulay
VM: Can we unlock the potential of IGF-1R inhibition in cancer
therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tsuta K, Mimae T, Nitta H, Yoshida A,
Maeshima AM, Asamura H, Grogan TM, Furuta K and Tsuda H:
Insulin-like growth factor-1 receptor protein expression and gene
copy number alterations in non-small cell lung carcinomas. Hum
Pathol. 44:975–982. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang X, Sun J, Wang H, Lou Y, Zhang Y,
Sha H, Feng J and Han B: IGF-1R and Bmi-1 expressions in lung
adenocarcinoma and their clinicopathologic and prognostic
significance. Tumour Biol. 35:739–745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wei YH, Tang HX, Liao YD, Fu SL, Xu LQ,
Chen G, Zhang C, Ju S, Liu ZG, You LK, et al: Effects of
insulin-like growth factor 1 receptor and its inhibitor AG1024 on
the progress of lung cancer. J Huazhong Univ Sci Technolog Med Sci.
35:834–841. 2015. View Article : Google Scholar : PubMed/NCBI
|
